What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker?
作者信息
Cohen Debbie L, Townsend Raymond R
机构信息
From the Department of Medicine, Hypertension Program, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
出版信息
J Clin Hypertens (Greenwich). 2008 Oct;10(10):803-4. doi: 10.1111/j.1751-7176.2008.00023.x.
Abstract
摘要
相似文献
1
What should the physician do when creatinine increases after starting an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker?开始使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂后肌酐升高时医生该怎么做？
J Clin Hypertens (Greenwich). 2008 Oct;10(10):803-4. doi: 10.1111/j.1751-7176.2008.00023.x.
2
[Antihypertensive drug therapy--combination of AT1-receptor blocker and betablocker].[抗高血压药物治疗——血管紧张素Ⅱ1型受体阻滞剂与β受体阻滞剂联合使用]
Dtsch Med Wochenschr. 2010 May;135(3):98. doi: 10.1055/s-0029-1244825. Epub 2010 Jan 14.
3
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.阿利吉仑与噻嗪类利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂联合使用时，可降低血压并抑制血浆肾素活性。
Hypertension. 2007 Feb;49(2):276-84. doi: 10.1161/01.HYP.0000253780.36691.4f. Epub 2006 Dec 11.
4
[Dual blockade of the renin-angiotensin system in hypertensive treatment: no].[肾素-血管紧张素系统双重阻断在高血压治疗中的应用：否定]
Dtsch Med Wochenschr. 2012 Nov;137(48):2499. doi: 10.1055/s-0032-1327302. Epub 2012 Nov 20.
5
Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.血管紧张素受体阻滞剂与其他药物在高血压、心血管疾病和肾病管理中的比较作用。
South Med J. 2009 Dec;102(12):1201-2. doi: 10.1097/SMJ.0b013e3181bef7bd.
6
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.在临床试验与常规实践中比较肾素-血管紧张素受体阻滞剂阿齐沙坦美洛昔酯与血管紧张素转换酶抑制剂雷米普利：来自前瞻性EARLY注册研究的见解
Trials. 2015 Dec 19;16:581. doi: 10.1186/s13063-015-1100-8.
7
Inhibitors of the renin angiotensin system: proven benefits, unproven safety.肾素血管紧张素系统抑制剂：已证实的益处，未证实的安全性。
Ann Intern Med. 2008 Jan 1;148(1):76-7. doi: 10.7326/0003-4819-148-1-200801010-00191. Epub 2007 Nov 5.
8
Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.在慢性肾病高血压患者中，低剂量氢氯噻嗪联合强化肾素-血管紧张素抑制治疗的肾脏保护及降压作用
Int J Clin Pharmacol Ther. 2009 Aug;47(8):525-32. doi: 10.5414/cpp47525.
9
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?替米沙坦与ONTARGET试验中的卒中减少：降压之外的获益？
Cerebrovasc Dis. 2008;26(5):563-4. doi: 10.1159/000164555. Epub 2008 Oct 21.
10
ACE inhibitors and ARBs: antihypertensive medications in CKD.
Nephrol Nurs J. 2005 May-Jun;32(3):332-3.
引用本文的文献
1
Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.达格列净治疗后估算肾小球滤过率（eGFR）斜率的有利变化及其与初始下降的关联。
Clin Exp Nephrol. 2024 Dec;28(12):1282-1289. doi: 10.1007/s10157-024-02532-4. Epub 2024 Jul 6.
2
Cardiovascular disease in patients with chronic kidney disease.慢性肾脏病患者的心血管疾病
Herz. 2020 Apr;45(2):122-128. doi: 10.1007/s00059-019-04884-0.
3
Managing hypertension in primary care.基层医疗中的高血压管理
Can Fam Physician. 2019 Oct;65(10):725-729.
本文引用的文献
1
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.《肾脏病预后质量倡议（K/DOQI）慢性肾脏病高血压及抗高血压药物临床实践指南》
Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290.
2
Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.慢性肾脏疾病：肾素-血管紧张素系统抑制的肾脏保护作用
Ann Intern Med. 2002 Apr 16;136(8):604-15. doi: 10.7326/0003-4819-136-8-200204160-00010.
3
Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience.
Arch Intern Med. 1994 Mar 14;154(5):513-23.
4
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).依那普利对严重充血性心力衰竭死亡率的影响。北欧依那普利生存协作研究（CONSENSUS）结果
N Engl J Med. 1987 Jun 4;316(23):1429-35. doi: 10.1056/NEJM198706043162301.
5
Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.
Ann Intern Med. 1991 Oct 1;115(7):513-9. doi: 10.7326/0003-4819-115-7-513.
Zotero 插件